Clinical effectiveness and safety of montelukast in asthma. what are the conclusions from clinical trials and meta-analyses?

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 839-850

  Hon, Kam Lun Ellis ^a   Leung, Ting Fan ^a   Leung, Alexander K C ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cysteinyl leukotriene receptor antagonist; Inhaled corticosteroid; Meta analysis; Randomized control trial

Indexed keywords

BECLOMETASONE; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; ZAFIRLUKAST; ZILEUTON; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; GLUCOCORTICOID; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ADVERSE OUTCOME; ARTHRALGIA; ARTICLE; ASTHMA; CLINICAL EFFECTIVENESS; COUGHING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; IMMUNOMODULATION; LOEFFLER PNEUMONIA; MONOTHERAPY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PHARMACOLOGICAL BLOCKING; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; SEIZURE; SLEEP DISORDER; SYSTEMATIC REVIEW; CHILD; CLINICAL TRIAL (TOPIC); MEDICATION COMPLIANCE; QUALITY OF LIFE;

ACETATES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CLINICAL TRIALS AS TOPIC; GLUCOCORTICOIDS; HUMANS; MEDICATION ADHERENCE; QUALITY OF LIFE; QUINOLINES;

EID: 84903391622     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S39100     Document Type: Article

References (106)

1. Becker A, Lemiere C, Berube D, et al. Summary of recommendations from the Canadian Asthma Consensus guidelines, 2003. CMAJ. 2005;173(6 Suppl):S3-S11.
2. Hon KL, Wang SS, Leung TF. The atopic march: from skin to the airways. Iran J Allergy Asthma Immunol. 2012;11(1):73-77.
3. Cannon E. Aligning patient care and asthma treatment guidelines. Am J Manag Care. 2005;11(Suppl 14):S416-S421quiz 427
4. Simpson EL, Hanifin JM. Atopic dermatitis. J Am Acad Dermatol. 2005;53(1):115-128.
5. Leung AK, Hon KL, Robson WL. Atopic dermatitis. Adv Pediatr. 2007;54:241-273.
6. Leung R, Wong G, Lau J, et al. Prevalence of asthma and allergy in Hong Kong schoolchildren: an ISAAC study. Eur Respir J. 1997;10(2): 354-360.
7. Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol. 2004;93(3 Suppl 2): S1-S21.
8. Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010;26(3):633-640.
9. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131(1):67-73.
10. Leung AK, Barber KA. Managing childhood atopic dermatitis. Adv Ther. 2003;20(3):129-137.
11. Li F, Zhou Y, Li S, et al. Prevalence and risk factors of childhood allergic diseases in eight metropolitan cities in China: a multicenter study. BMC Public Health. 2011;11:437.
12. Hon KL, Nelson EA. Gender disparity in paediatric hospital admissions. Ann Acad Med Singapore. 2006;35(12):882-888.
13. Bufford JD, Gern JE. The hygiene hypothesis revisited. Immunol Allergy Clin North Am. 2005;25(2):247-262
14. Flohr C, Yeo L. Atopic dermatitis and the hygiene hypothesis revisited. Curr Probl Dermatol. 2011;41:1-34.
15. Patterson R, Walker CL, Greenberger PA, Sheridan EP. Prednisonephobia. Allergy Proc. 1989;10(6):423-428.
16. Tuft L. "Steroid-phobia" in asthma management. Ann Allergy. 1979;42(3):152-159.
17. Zedan MM, Ezz El Regal M, A Osman E, E Fouda A. Steroid phobia among parents of asthmatic children: myths and truth. Iran J Allergy Asthma Immunol. 2010;9(3):163-168.
18. Skoner JD, Schaffner TJ, Schad CA, Kwon AY, Skoner DP. Addressing steroid phobia: improving the risk-benefit ratio with new agents. Allergy Asthma Proc. 2008;29(4):358-364.
19. Hon KL, Tang WS, Leung TF, Cheung KL, Ng PC. Outcome of children with life-threatening asthma necessitating pediatric intensive care. Ital J Pediatr. 2010;36:47.
20. Hon KL, Kam WY, Leung TF, et al. Steroid fears in children with eczema. Acta Paediatr. 2006;95(11):1451-1455.
21. Chen HY, Lin YH, Thien PF, et al. Identifying core herbal treatments for children with asthma: implication from a chinese herbal medicine database in taiwan. Evid Based Complement Alternat Med. 2013;2013: 125943.
22. Hon KL, Leung TF, Ma KC, Wong Y, Fok TF. Brief case series: montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis. J Dermatolog Treat. 2005;16(1):15-18.
23. Hon KLE, Leung TF. Killing many birds with one stone. HK J Paediatr. 2008;13:135-138.
24. Chu HW, Martin RJ. Are eosinophils still important in asthma? Clin Exp Allergy. 2001;31(4):525-528.
25. Sampson AP. The role of eosinophils and neutrophils in inflammation. Clin Exp Allergy. 2000;30(Suppl 1):22-27.
26. Williams TJ. The eosinophil enigma. J Clin Invest. 2004;113(4): 507-509.
27. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002;346(22):1699-1705.
28. Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol. 1995;95(4):843-852.
29. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1532-1539.
30. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med. 1997;156(3 Pt 1):737-743.
31. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368(9537):804-813.
32. Peters-Golden M. The alveolar macrophage: the forgotten cell in asthma. Am J Respir Cell Mol Biol. 2004;31(1):3-7.
33. Kuipers H, Lambrecht BN. The interplay of dendritic cells, Th2 cells and regulatory T cells in asthma. Curr Opin Immunol. 2004;16(6): 702-708.
34. Polito AJ, Proud D. Epithelia cells as regulators of airway inflammation. J Allergy Clin Immunol. 1998;102(5):714-718.
35. Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol. 2004;22:789-815.
36. Akbari O, Faul JL, Hoyte EG, et al. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N Engl J Med. 2006;354(11): 1117-1129.
37. Larché M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol. 2003;111(3):450-463quiz 464
38. Barnes PJ. Cytokine modulators as novel therapies for asthma. Annu Rev Pharmacol Toxicol. 2002;42:81-98.
39. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME. Chemokines in asthma: cooperative interaction between chemokines and IL-13. J Allergy Clin Immunol. 2003;111(2):227-242 quiz 243
40. Leung TF, Wong CK, Chan IH, Ip WK, Lam CW, Wong GW. Plasma concentration of thymus and activation-regulated chemokine is elevated in childhood asthma. J Allergy Clin Immunol. 2002;110(3): 404-409.
41. Boyce JA. Mast cells: beyond IgE. J Allergy Clin Immunol. 2003;111(1): 24-32quiz 33.
42. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005;23:749-786.
43. Robinson DS. The role of the mast cell in asthma: induction of airway hyperresponsiveness by interaction with smooth muscle? J Allergy Clin Immunol. 2004;114(1):58-65.
44. Busse WW. The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy. 1996;26(8):868-879.
45. Leff AR. Regulation of leukotrienes in the management of asthma: biology and clinical therapy. Annu Rev Med. 2001;52:1-14.
46. Gelfand EW, Dakhama A. CD8+ T lymphocytes and leukotriene B4: novel interactions in the persistence and progression of asthma. J Allergy Clin Immunol. 2006;117(3):577-582.
47. Deykin A, Massaro AF, Drazen JM, Israel E. Exhaled nitric oxide as a diagnostic test for asthma: online versus offline techniques and effect of flow rate. Am J Respir Crit Care Med. 2002;165(12):1597-1601.
48. Strunk RC, Szefler SJ, Phillips BR, et al; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. J Allergy Clin Immunol. 2003;112(5):883-892.
49. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715-1721.
50. Hon KL, Leung TF, Kam WY, et al. Exhaled nitric oxide levels are not correlated with eczema severity in Chinese children with atopic dermatitis. J Asthma. 2006;43(6):417-419.
51. Sporik R, Ingram JM, Price W, Sussman JH, Honsinger RW, Platts-Mills TA. Association of asthma with serum IgE and skin test reactivity to allergens among children living at high altitude. Tickling the dragon's breath. Am J Respir Crit Care Med. 1995;151(5): 1388-1392.
52. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190.
53. Holgate S, Casale T, Wenzel S, Bousquet J, Deniz Y, Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol. 2005;115(3): 459-465.
54. van der Wiel E, ten Hacken NH, Postma DS, van den Berge M. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol. 2013;131(3):646-657.
55. Zubairi AB, Salahuddin N, Khawaja A, et al. A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation. BMC Pulm Med. 2013;13:20.
56. Dahlén SE. Treatment of asthma with antileukotrienes: first line or last resort therapy? Eur J Pharmacol. 2006;533(1-3):40-56.
57. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108(3):E48.
58. van Adelsberg J, Moy J, Wei LX, Tozzi CA, Knorr B, Reiss TF. Safety, tolerability, and exploratory efficacy of montelukast in 6- to 24-month-old patients with asthma. Curr Med Res Opin. 2005;21(6): 971-979.
59. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr. 2001;138(5):694-698.
60. Knuffman JE, Sorkness CA, Lemanske RF Jr, et al; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma. J Allergy Clin Immunol. 2009;123(2):411-416.
61. Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010;4:CD005533.
62. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev. 2011;5:CD003137.
63. Brand PL. Inhaled corticosteroids should be the first line of treatment for children with asthma. Paediatr Respir Rev. 2011;12(4):245-249.
64. Nathan RA, Kemp JP; Antileukotriene Working Group. Efficacy of antileukotriene agents in asthma management. Ann Allergy Asthma Immunol. 2001;86(6 Suppl 1):9-17.
65. Grzelewski T, Stelmach I. Exercise-induced bronchoconstriction in asthmatic children: a comparative systematic review of the available treatment options. Drugs. 2009;69(12):1533-1553.
66. Blake KV. Montelukast: data from clinical trials in the management of asthma. Ann Pharmacother. 1999;33(12):1299-1314.
67. Peng WS, Chen X, Yang XY, Liu EM. Systematic review of montelukast's efficacy for preventing post-bronchiolitis wheezing. Pediatr Allergy Immunol. 2014;25(2):143-150.
68. Currie GP, McLaughlin K. The expanding role of leukotriene receptor antagonists in chronic asthma. Ann Allergy Asthma Immunol. 2006;97(6):731-741. quiz 741.
69. Spector SL; Antileukotriene Working Group. Safety of antileukotriene agents in asthma management. Ann Allergy Asthma Immunol. 2001; 86(6 Suppl 1):18-23.
70. Baek HS, Cho J, Kim JH, Oh JW, Lee HB. Ratio of leukotriene e(4) to exhaled nitric oxide and the therapeutic response in children with exercise-induced bronchoconstriction. Allergy Asthma Immunol Res. 2013;5(1):26-33.
71. Wasfi YS, Kemp JP, Villarán C, et al. Onset and duration of attenuation of exercise-induced bronchoconstriction in children by single-dose of montelukast. Allergy Asthma Proc. 2011;32(6):453-459.
72. Fogel RB, Rosario N, Aristizabal G, et al. Effect of montelukast or salmeterol added to inhaled fluticasone on exercise-induced bronchoconstriction in children. Ann Allergy Asthma Immunol. 2010;104(6): 511-517.
73. Tecklenburg-Lund S, Mickleborough TD, Turner LA, Fly AD, Stager JM, Montgomery GS. Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction. PLoS One. 2010;5(10): e13487.
74. Wang K, Birring SS, Taylor K, et al. Montelukast for postinfectious cough in adults: a double-blind randomised placebo-controlled trial. Lancet Respir Med. 2014;2(1):35-43.
75. Price D, Popov TA, Bjermer L, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013;131(3):763-771.
76. Lazarus SC, Chinchilli VM, Rollings NJ, et al; National Heart Lung and Blood Institute's Asthma Clinical Research Network. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175(8): 783-790.
77. Melo RE, Solé D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. J Allergy Clin Immunol. 2003;111(2):301-307.
78. Tomita K, Sano H, Iwanaga T, et al. Association between episodes of upper respiratory infection and exacerbations in adult patients with asthma. J Asthma. 2012;49(3):253-259.
79. Sadatsafavi M, Lynd L, Marra C, Bedouch P, Fitzgerald M. Comparative outcomes of leukotriene receptor antagonists and long-acting β-agonists as add-on therapy in asthmatic patients: a population-based study. J Allergy Clin Immunol. 2013;132(1):63-69.
80. Matsuse H, Fukahori S, Tsuchida T, et al. Effects of a short course of pranlukast combined with systemic corticosteroid on acute asthma exacerbation induced by upper respiratory tract infection. J Asthma. 2012;49(6):637-641.
81. Matsuse H, Tsuchida T, Fukahori S, et al. Retrospective cohort study of leukotriene receptor antagonist therapy for preventing upper respiratory infection-induced acute asthma exacerbations. Allergy Rhinol (Providence). 2013;4(3):e127-e131.
82. Mustafa FH, Salem NA, Daham M. Therapeutic and some biochemical studies of montelukast and ketotifen in children with mild asthma. Global J Med Res. 2012; 12Ver 1.0.
83. Chauhan BF, Ben Salah R, Ducharme FM. Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthma. Cochrane Database Syst Rev. 2013;10:CD009585.
84. Capsomidis A, Tighe M. Archimedes. Question 2. Is oral montelukast beneficial in treating acute asthma exacerbations in children? Arch Dis Child. 2010;95(11):948-950.
85. Camargo CA, Boulet LP, Sutherland ER, et al. Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. J Asthma. 2010;47(1):76-82.
86. Castro-Rodriguez JA, Rodrigo GJ. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis. Arch Dis Child. 2010;95(5): 365-370.
87. Philip G, Swern AS, Smugar SS, Pearlman DS. Baseline predictors of placebo response in exercise-induced bronchoconstriction (EIB): pooled regression analysis. from three studies of montelukast in EIB. J Asthma. 2010;47(8):935-941.
88. Miceli Sopo S, Onesimo R, Radzik D, Scala G, Cardinale F. Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best? Allergol Immunopathol (Madr). 2009; 37(1):26-30.
89. Joos S, Miksch A, Szecsenyi J, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax. 2008;63(5):453-462.
90. Jartti T. Inhaled corticosteroids or montelukast as the preferred primary long-term treatment for pediatric asthma? Eur J Pediatr. 2008;167(7):731-736.
91. Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev. 2006;4:CD003137.
92. Akazawa M, Stempel DA. Single-inhaler combination therapy for asthma: a review of cost effectiveness. Pharmacoeconomics. 2006; 24(10):971-988.
93. Allen-Ramey FC, Bukstein D, Luskin A, Sajjan SG, Markson LE. Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. J Manag Care Pharm. 2006; 12(4):310-321.
94. Bracken MB, Triche EW, Belanger K, Saftlas A, Beckett WS, Leaderer BP. Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies. Obstet Gynecol. 2003;102(4): 739-752.
95. Gluck JC, Gluck PA. Asthma controller therapy during pregnancy. Am J Obstet Gynecol. 2005;192(2):369-380.
96. Ram FS, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev. 2005;1:CD003137.
97. Korenblat PE; Antileukotriene Working Group. The role of antileukotrienes in the treatment of asthma. Ann Allergy Asthma Immunol. 2001;86(6 Suppl 1):31-39.
98. Price DB, Ben-Joseph RH, Zhang Q. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the UK. Respir Med. 2001;95(1):83-89.
99. Lenney W, McKay AJ, Tudur Smith C, Williamson PR, James M, Price D; MASCOT Study Group. Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. Health Technol Assess. 2013;17(4):1-218.
100. Kubavat AH, Khippal N, Tak S, et al. A randomized, comparative, multicentric clinical trial to assess the efficacy and safety of zileuton extended-release tablets with montelukast sodium tablets in patients suffering from chronic persistent asthma. Am J Ther. 2013;20(2): 154-162.
101. Ramsay CF, Pearson D, Mildenhall S, Wilson AM. Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial. Thorax. 2011;66(1):7-11.
102. Olszowiec-Chlebna M, Majak P, Brzozowska A, Bobrowska-Korzeniowska M, Jerzynska J, Stelmach I. Effect of inhaled steroid and montelukast on clinical symptoms in children with newly diagnosed asthma: a pilot study. Pediatr Allergy Immunol. 2010;21(4 Pt 2): e687-e690.
103. Todi VK, Lodha R, Kabra SK. Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial. Arch Dis Child. 2010;95(7):540-543.
104. Nelson KA, Smith SR, Trinkaus K, Jaffe DM. Pilot study of oral montelukast added to standard therapy for acute asthma exacerbations in children aged 6 to 14 years. Pediatr Emerg Care. 2008;24(1):21-27.
105. Johnston NW, Mandhane PJ, Dai J, et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics. 2007;120(3):e702-e712.
106. Harmanci K, Bakirtas A, Turktas I, Degim T. Oral montelukast treatment of preschool-aged children with acute asthma. Ann Allergy Asthma Immunol. 2006;96(5):731-735.